Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors

Hanmi Pharmaceutical

Status and phase

Enrolling

Phase 1

Conditions

Advanced or Metastatic Solid Tumors

Treatments

Drug: HM97662

Study type

Interventional

Funder types

Industry

Identifiers

NCT05598151

HM-EZHI-101

Details and patient eligibility

About

This is a Phase1 study to assess the safety, PK, PD and efficacy of HM97662, EZH1/2 dual inhibitor, in solid tumors. The study is comprised of Dose-Escalation Part followed by randomized Dose-Ranging Part and Dose-Expansion Part. Dose-Escalation Part is planned with a 3+3 Dose-Escalation design and is to establish the MTD or RD for randomized Dose-Ranging Part. Dose-Ranging Part is designed mainly to further evaluate safety and preliminary efficacy of HM97662 monotherapy in subjects with specific genomic alterations to more precisely determine the potential RP2D that are to be tested in a Dose-Expansion Part. Dose-Expansion Part is designed to assess the potential efficacy of HM97662 monotherapy when administered at the RP2D to subjects in indication-specific expansion cohorts.

Enrollment

170 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically and/or cytologically confirmed advanced or metastatic solid tumor who have failed/are intolerant to standard therapy.
Patients for dose-escalation part must have evaluable or measurable disease at baseline and the patients for randomized dose-ranging and dose-expansion part must have at least one measurable lesion at baseline by CT or MRI per Response Evaluation Criteria in Solid Tumor (RECIST v1.1).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy ≥ 3 months before starting HM97662.
Adequate renal function.
Adequate hematologic function.
Adequate liver function.
Males or females aged ≥ 18 years (or country's legal age of majority if the legal age was > 18 years) at the time of informed consent.
For Dose-Ranging Part, documentation of an alteration in at least one of the genes of the SWI/SNF complex in tumor tissue (archival or newly obtained).

Exclusion criteria

Prior exposure to valemetostat or other EZH1/2 dual inhibitor.
Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms.
Patients currently taking medications that are known strong CYP3A inhibitors and strong or moderate CYP3A inducers.
Any prior treatment-related (i.e. chemotherapy, immunotherapy, radiotherapy) clinically significant toxicities that have not resolved to Grade ≤ 1 per CTCAE version 5.0 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrollment.
Major surgery within 4 weeks before the first dose of study drug treatment in Cycle 1.
Females who are pregnant or breastfeeding.
Patients who have undergone an organ transplant.